Amalgamated Bank’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,217
| Closed | -$5K | – | 3039 |
|
|
2025
Q2 | $5K | Hold |
1,217
| – | – | ﹤0.01% | 2795 |
|
|
2025
Q1 | $5K | Hold |
1,217
| – | – | ﹤0.01% | 2700 |
|
|
2024
Q4 | $10K | Hold |
1,217
| – | – | ﹤0.01% | 2454 |
|
|
2024
Q3 | $16K | Hold |
1,217
| – | – | ﹤0.01% | 2238 |
|
|
2024
Q2 | $15K | Hold |
1,217
| – | – | ﹤0.01% | 2254 |
|
|
2024
Q1 | $20K | Sell |
1,217
-2,904
| -70% | -$39.1K | ﹤0.01% | 2134 |
|
|
2023
Q4 | $28K | Sell |
4,121
-362
| -8% | -$2.09K | ﹤0.01% | 2506 |
|
|
2023
Q3 | $24K | Hold |
4,483
| – | – | ﹤0.01% | 2568 |
|
|
2023
Q2 | $30K | Sell |
4,483
-566
| -11% | -$4.24K | ﹤0.01% | 2535 |
|
|
2023
Q1 | $25K | Sell |
5,049
-770
| -13% | -$3.14K | ﹤0.01% | 2571 |
|
|
2022
Q4 | $28K | Hold |
5,819
| – | – | ﹤0.01% | 2655 |
|
|
2022
Q3 | $84K | Buy |
5,819
+92
| +2% | +$1.52K | ﹤0.01% | 2233 |
|
|
2022
Q2 | $87K | Buy |
5,727
+21
| +0.4% | +$245 | ﹤0.01% | 2229 |
|
|
2022
Q1 | $68K | Buy |
+5,706
| New | +$58.6K | ﹤0.01% | 2329 |
|
|
2021
Q3 | – | Sell |
-6,599
| Closed | -$223K | – | 2182 |
|
|
2021
Q2 | $223K | Buy |
+6,599
| New | +$212K | ﹤0.01% | 1995 |
|
|
2021
Q1 | – | Sell |
-4,764
| Closed | -$236K | – | 1627 |
|
|
2020
Q4 | $236K | Buy |
+4,764
| New | +$220K | 0.01% | 1358 |
|
|
2020
Q3 | – | Sell |
-4,792
| Closed | -$207K | – | 1520 |
|
|
2020
Q2 | $207K | Buy |
+4,792
| New | +$181K | 0.01% | 1287 |
|
Other funds holding YMAB
Amalgamated Bank's YMAB Position: Q3 2025 in Review
Amalgamated Bank sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 1,217 shares — an estimated $5K sold.
Amalgamated Bank first reported a position in YMAB in Q2 2020 and held it in 17 quarters. The position peaked at $236K in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Amalgamated Bank reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Amalgamated Bank sold 1,217 Y-mAbs Therapeutics shares in Q3 2025, an estimated $5K.
- Amalgamated Bank first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 17 quarters.
- Amalgamated Bank's Y-mAbs Therapeutics position peaked at $236K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Amalgamated Bank's 13F filing for Q3 2025, filed 29 Oct 2025.